Zoetis (ZTS) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
15 Jun, 2026Purpose and vision
Aims to nurture the world by advancing animal care and aspires to be the most trusted and valued animal health company through innovation and customer focus.
Business overview and scale
Operates in over 100 countries with $9.5B annual revenue and 14,500 employees worldwide.
Offers medicines, vaccines, diagnostics, biodevices, and genetic tests across 8 core species.
70% of revenue comes from companion animal products, 30% from livestock.
18 blockbuster products each generate over $100M annually.
Strategic priorities
Focuses on innovation, customer experience, digital solutions, colleague development, sustainability, and operational excellence.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Zoetis
- Q2 2026 revenue flat; U.S. Companion Animal down, Livestock and International segments up; guidance cut.ZTS
Q2 2026 - Strong growth, innovation, and channel expansion offset tariff risks and competitive pressures.ZTS
Stifel Jaws & Paws Conference 2025 - Tariff impacts are managed, innovation and alternative channels drive sustained growth.ZTS
BNP Paribas 2nd Annual Animal Health Day - Above-market growth driven by innovation, strong franchises, and strategic R&D investment.ZTS
Piper Sandler 36th Annual Healthcare Conference - Innovation pipeline and global diversification drive growth despite macro and competitive headwinds.ZTS
46th Annual William Blair Growth Stock Conference - 2026 growth guided at 2%-5%, with innovation and targeted promotions offsetting competition.ZTS
Stifel Jaws & Paws Conference 2026 - Solid growth, innovation focus, and recovery plans highlighted amid competitive pressures.ZTS
AGM 2026 - Q3 2024 delivered 14% operational revenue growth and raised guidance, led by key franchises.ZTS
Q3 2024 - Q1 2025 saw 9% organic revenue growth and raised adjusted EPS guidance to $6.20–$6.30.ZTS
Q1 2025